Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-305-7777
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$350,000.00
Profitability
Miscellaneous
Employees251
OptionableOptionable
Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics Inc (NASDAQ:FLXN) posted its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.06. The specialty pharmaceutical company had revenue of $3.80 million for the quarter, compared to analysts' expectations of $3.96 million. Flexion Therapeutics had a negative net margin of 1,346.87% and a negative return on equity of 88.21%. View Flexion Therapeutics' Earnings History.
When is Flexion Therapeutics' next earnings date?
What price target have analysts set for FLXN?
4 Wall Street analysts have issued 12 month price targets for Flexion Therapeutics' stock. Their forecasts range from $11.49 to $36.00. On average, they expect Flexion Therapeutics' share price to reach $26.8725 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.
What is the consensus analysts' recommendation for Flexion Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.
Has Flexion Therapeutics been receiving favorable news coverage?
Press coverage about FLXN stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Flexion Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Insmed (INSM), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Endocyte (ECYT), Enanta Pharmaceuticals (ENTA), AnaptysBio (ANAB), Mallinckrodt (MNK), Madrigal Pharmaceuticals (MDGL), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO) and Myokardia (MYOK).
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the folowing people:
- Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)
- Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)
- Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)
- Mr. David A. Arkowitz, Chief Financial Officer (Age 58)
- Scott Young, VP of Corp. Communications & Investor Relations
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.55%), Peregrine Capital Management LLC (2.04%), Rhenman & Partners Asset Management AB (1.34%), Northern Trust Corp (1.18%), Geode Capital Management LLC (1.02%) and Gagnon Securities LLC (0.67%). Company insiders that own Flexion Therapeutics stock include David Arkowitz, Frederick W Driscoll, Mark S Levine, Mark Stejbach, Michael D Clayman, Neil Bodick and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.
Which institutional investors are selling Flexion Therapeutics stock?
FLXN stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Zweig DiMenna Associates LLC, Squarepoint Ops LLC, Rhenman & Partners Asset Management AB, GAM Holding AG, Northern Trust Corp, Gagnon Advisors LLC and BlackRock Inc.. Company insiders that have sold Flexion Therapeutics company stock in the last year include Mark S Levine, Michael D Clayman and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.
Which institutional investors are buying Flexion Therapeutics stock?
FLXN stock was purchased by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Canada Pension Plan Investment Board, Virtu Financial LLC, Alps Advisors Inc., Rhumbline Advisers, Metropolitan Life Insurance Co. NY, Geode Capital Management LLC and Next Capital Management LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include David Arkowitz, Mark Stejbach, Michael D Clayman, Neil Bodick and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.
How do I buy shares of Flexion Therapeutics?
Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flexion Therapeutics' stock price today?
One share of FLXN stock can currently be purchased for approximately $14.66.
How big of a company is Flexion Therapeutics?
Flexion Therapeutics has a market capitalization of $554.98 million and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.
What is Flexion Therapeutics' official website?
How can I contact Flexion Therapeutics?
Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]
MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
